Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Assets (2017 - 2025)

Historic Current Assets for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $182.1 million.

  • Sutro Biopharma's Current Assets fell 5512.02% to $182.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.1 million, marking a year-over-year decrease of 5512.02%. This contributed to the annual value of $343.3 million for FY2024, which is 1855.85% down from last year.
  • As of Q3 2025, Sutro Biopharma's Current Assets stood at $182.1 million, which was down 5512.02% from $231.6 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Current Assets registered a high of $443.5 million during Q2 2024, and its lowest value of $182.1 million during Q3 2025.
  • Moreover, its 5-year median value for Current Assets was $331.5 million (2022), whereas its average is $317.9 million.
  • As far as peak fluctuations go, Sutro Biopharma's Current Assets soared by 10869.53% in 2021, and later plummeted by 5512.02% in 2025.
  • Over the past 5 years, Sutro Biopharma's Current Assets (Quarter) stood at $218.5 million in 2021, then skyrocketed by 61.61% to $353.2 million in 2022, then rose by 19.37% to $421.5 million in 2023, then decreased by 18.56% to $343.3 million in 2024, then plummeted by 46.95% to $182.1 million in 2025.
  • Its Current Assets was $182.1 million in Q3 2025, compared to $231.6 million in Q2 2025 and $287.4 million in Q1 2025.